Novavax (NVAX) slashed its 2022 outlook late Monday, citing “evolving market dynamics” going through its Covid vaccine. NVAX inventory crashed.
X
The determination adopted a serious second-quarter disappointment wherein gross sales got here in at lower than one-fifth what analysts projected. Further, Novavax reported an surprising loss that widened vs. final 12 months’s second quarter. Wall Street had anticipated Novavax to tack on a second straight quarter of beneficial properties.
In after-hours buying and selling on right now’s inventory market, NVAX inventory plummeted 33.1% close to 38.30.
“Today, Novavax adjusted steerage for 2022 to account for a number of evolving market dynamics,” the corporate mentioned in a written assertion. “We stay assured in our vaccine as a powerful further selection. Its aggressive product profile consists of our vaccine’s (effectiveness), well-tolerated security profile, sturdiness of safety, and talent to handle each present and future variant strains.”
NVAX Stock: Differentiating From Pfizer, Moderna
Novavax is banking on its protein know-how to distinguish it from Pfizer’s (PFE) and Moderna’s (MRNA) messenger-RNA-based Covid pictures. Novavax’s vaccine is out there to adults in 43 international locations together with the U.S. It additionally has a booster shot in three international locations.
But traders hammered NVAX inventory after the second-quarter report. Sales tumbled practically 38% to $185.9 million and missed forecasts for $1.02 billion. Novavax additionally misplaced $6.53 per share. Analysts anticipated a per-share acquire of $5.54. Losses additionally widened from $4.75 within the year-earlier interval.
The firm says it is making “super progress” within the third quarter and has already shipped greater than 23 million doses for the reason that starting of July.
“While in some instances supply could also be pushed into 2023, we don’t count on complete contracted demand to alter beneath nearly all of our advance buy agreements,” Novavax mentioned.
Still, the corporate lower its 2022 outlook in half and now expects $2 billion to $2.3 billion in gross sales. That pales compared to NVAX inventory analysts’ name for $4.27 billion. Still, gross sales would practically double on the midpoint of Novavax’s steerage.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Top-Notch Karuna Therapeutics Breaks Out To Record High On Schizophrenia Win
Why Pfizer’s $5.4 Billion GBT Takeover Is ‘Mutually Beneficial’
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
Watch IBD’s Investing Strategies Show For Actionable Market Insights
IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today